Publications and Presentations

Check out our publications and poster presentations.

November 2020

Anti-Tumor Activity of A Small Molecule Inhibitor of the Immuno-Suppressive Enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)

The Society for Immunotherapy of Cancer

October 2020

A phase 1B randomized, double-blind, placebo-controlled trial to evaluate CB-280 in patients with cystic fibrosis

North American Cystic Fibrosis Conference

May 2020

KEAPSAKE Trial-in Progress: A Phase 2 Randomized Study of Telaglenastat, a Glutaminase Inhibitor, vs. Placebo, in Combination w/ Pembrolizumab and Chemotherapy as First-Line Treatment for KEAP1/NRF2-Mutated Non-Squamous Metastatic Non-Small Cell Lung Cancer

American Society of Clinical Oncology

December 2019

Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)

American Society of Hematology

November 2019

CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity

The Society for Immunotherapy of Cancer

Our Pipeline

We are focused on novel treatments for
cancer and other life-threatening diseases.

View Our Pipeline